小程序掃碼下單
本網(wǎng)站銷(xiāo)售的所有產(chǎn)品僅用于工業(yè)應(yīng)用或者科學(xué)研究等非醫(yī)療目的，不可用于人類(lèi)或動(dòng)物的臨床診斷或者治療，非藥用，非食用。
阿維魯單抗
英文名：Avelumab
Cas號(hào)：1537032-82-8
Cas號(hào)：1537032-82-8
檢測(cè)信息查詢(xún)
| 貨號(hào) | 規(guī)格 | 貨期 | 庫(kù)存 | 價(jià)格 | 促銷(xiāo)價(jià) | 訂購(gòu) |
| 1308132488-1mg | 0 | ￥17000 | ||||
| 1308132488-5mg | 0 | ￥50000 |
| 別 名 | |
| Cas號(hào) | 1537032-82-8 |
| M D L | |
| 分子式 | |
| 分子量 | |
| 產(chǎn)品參數(shù) | Description
Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity. IC50 & Target PD-1/PD-L1[1] References [1]. Fujii R, et al. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. Oncotarget. 2016 Jun 7;7(23):33498-511. [2]. Grenga I, et al. A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses. Clin Transl Immunology. 2016 May 20;5(5):e83. [3]. Vandeveer AJ, et al. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor. Cancer Immunol Res. 2016 May;4(5):452-62. |
| 性狀 | Avelumab 是一個(gè)人 IgG1 抗 PD-L1 單克隆抗體，具有潛在的抗體依賴(lài)性細(xì)胞介導(dǎo)的細(xì)胞毒性作用。 |
| 貯存 | Storage Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
滬公網(wǎng)安備 31012002003054號(hào)